黄片在线免费观看,欧美在线无码精品秘 蜜桃.,苍井空一级婬片A片,精品人妻一区二区三区日产乱码,鲁大师在线观看日本影片

English

ENDPOINTSNEWS: On a quest to challenge Novo Nordisk in obesity, transpacific startup picks up $70M — and a pair of seasoned execs

2021-10-13

新聞截圖.png

— AUTHOR: Amber Tong, Senior Editor

— REPRINTED FROM ENDPOINTSNEWS

— ORIGINAL LINK: https://endpts.com/on-a-quest-to-challenge-novo-nordisk-in-obesity-transpacific-startup-picks-up-70m-and-a-pair-of-seasoned-execs/

Four years after starting Terns Pharmaceuticals together in search of an elusive NASH win, Weidong Zhong and Martijn Fenaux are reuniting at a new startup.

On paper, Sciwind Biosciences — which just raised $70 million in Series C cash — employs a similar setup as Terns: Both have embraced the transpacific model, taking root in China but planting flags in the US.

Zhong was tapped to be president of the San Francisco-based subsidiary back in July, on top of assuming the role as chief strategy officer. Weeks later, Fenaux has been appointed SVP, nonclinical development and translational science at the parent company out of Hangzhou — joining the team alongside chief scientific officer Xinle Wu, who brings experience running R&D for both Eli Lilly and Amgen in China.

Whereas Terns is focused on NASH and other liver diseases, Sciwind positions itself as a specialist in metabolic disorders. The three lead candidates all congregate around GLP-1 receptor agonism, a mechanism that Sciwind reckons is relevant across fatty liver, obesity and diabetes.

The new infusion marks Sciwind’s second financing in a year, having bagged $37 million in February to fuel the clinical work underway for XW003 (long-acting GLP-1 peptide analog) in type 2 diabetes and obesity. Topline Phase II data are expected in the second half of 2022.

To reach those massive markets, the biotech would first have to steer past giant rivals like Novo Nordisk, whose GLP-1 peptide analog semaglutide is already approved in the US for both of those indications.

Then there's the follow-on XW004, which is designed for once daily rather than once weekly administration, slated for first-in-human trials later this year; and XW014, a preclinical small molecule GLP-1R agonist.

But IDG Capital, Loyal Valley Capital and LYFE Capital have no trouble believing in Sciwind and founder/CEO Hai Pan, leading the latest round.

无码精品人妻一区二区三区芙青椒 | 91九色丨国产丨人妻在线 | 成av人片一区二区三区久久 | 黄色视频在线观看免费阅读 | 在线国产精品免费播放 | 蜜桃Av噜噜一区二区三区小说 | 色狠狠色噜噜AV天堂五区消防 | 中文字幕AV在线中文字幕 | 四虎8848成人免费观看 | 欧美性受XXXX黑人XYX性爽公 | 先锋影音资源在线观看 | 国產又粗又猛又爽又黄 | 无码国产精品一区二区免费式直播 | 国精产品秘 福利姬视频 | 无码中文欧美精品A片谁看了 | 国产日韩精品无码区免费专区国产 | 亚洲第一视频网站 | 中国一级毛片免费播放 | 影音先锋AV资源网站 | aaaaaaaa在线观看 | 国产黃色A片三級三級三級老牛 | 欧美成人网站在线观看 | 中文字幕av一区二区三区佐山爱 | 樱桃国产成人精品视频 | 国产极品黑丝美女裸体被操免费网站 | 久久武侠古典第一页 | 中文字幕一区二区三区伦理影院 | 噜噜噜噜噜噜av中文字幕 | 欧美精品 - 91爱爱 | 啪啪啪欧美吸奶三级视频 | 欧美一性一交一免费看 | 又硬又粗进去爽A片免费无码安娜 | 婷婷开心激情综合五月天 | 一区二区三区在线播放 | 漂亮少妇高潮A片XXXX | 人体一级片在线播放 | 日本无码熟人中文字幕 | 18j禁羞羞在线 | 18岁美女污污污网站 | 精品秘 无码一区二区三 | 91人人爽日日精品国产 |